TiGenix uniquely combines early stage revenues from its ChondroCelect sales with the mid- to long-term commercial potential from its expanded adipose stem cell pipeline
The company’s lead product, ChondroCelect, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated: Cx601, Phase III clinical trial to treat complex perianal fistula in patients with Crohn’s, a Phase IIa trial in rheumatoid arthritis ongoing, and a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders.
Developed by Web4Bio